Aardvark Therapeutics, Inc. (AARD) Stock

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is led by CEO Tien-Li Lee, employs 22 people, headquartered in US, publicly traded since 2025.

Aardvark Therapeutics, Inc. (AARD) stock trades at $1.39 with a market capitalization of $30.42M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.55, reflecting a net loss over the last twelve months, price-to-book of 1.46, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.39 and $17.94, and currently trades 92.3% below its 52-week high.

On profitability, Aardvark Therapeutics, Inc. generates a return on equity (ROE) of -71.54% (negative, reflecting a net loss), return on capital employed of -98.51%.

Aardvark Therapeutics, Inc. by the numbers, 2022–2025

Between 2022 and 2025 Aardvark Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-58.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-70.0M.

Borrowings stand at $0, cash from operations was $-54.0M in the latest year, positive in 0 of the last 4.

Return on equity has averaged 13.5% over five years, and was -54.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Aardvark Therapeutics, Inc. (AARD) — frequently asked questions